Wave Life Sciences shares plunge as data for high dose of obesity drug disappoints

Wave Life Sciences shares plunge as data for high dose of obesity drug disappoints | Reuters But results from a 400 mg dose after three months showed only about a 5% reduction in visceral fat. "Investors are likely discouraged by the 400 mg data at 3 months, which look similar on visceral fat as 240 mg and not as good on total fat and lean mass, though there appear to be some differences in the baseline BMI and body composition of this cohort that could explain some of these observations," said a Leerink Pa ...